Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 215

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 215
---
 combinations and investments. In
addition, another entity may pursue us or certain of our assets or aspects of our operations as an acquisition target. Any such transactions
may require us to incur expenses specific to the transaction and not incident to our operations, may increase our near- and long-term
expenditures, may pose significant integration challenges, may require us to hire or otherwise engage personnel with additional expertise,
or may result in our selling or licensing of our assets or technologies under terms that may not prove profitable, any of which could
harm our operations and financial results. Such transactions may also entail numerous other operational and financial risks, including,
among others, exposure to unknown liabilities, disruption of our business and diversion of our management’s time and attention
in order to develop acquired products, drug candidates, technologies or businesses.

As part of our efforts to complete
any significant transaction, we would need to expend significant resources to conduct business, regulatory, legal and financial due diligence,
with the goal of identifying and evaluating material risks involved in the transaction. We may be unsuccessful in ascertaining or evaluating
all the risks and, as a result, we may not realize the expected benefits of the transaction, whether due to unidentified risks, integration
difficulties, regulatory setbacks or other events. We may incur material liabilities for the past activities of any businesses we partner
with or acquire. If any of these events occur, we could be subject to significant costs and damage to our reputation, business, results
of operations and financial condition.

If we are unable to establish, train and maintain
an effective sales and marketing infrastructure, we will not be able to commercialize our drug candidates successfully.

We have built an internal sales
and marketing infrastructure to implement our business plan by developing internal sales teams and education campaigns to market our
proprietary formulations and FDA-approved drug products. We will need to expend significant resources to further establish and grow this
internal infrastructure and properly train sales personnel with respect to regulatory compliance matters. We may also choose to engage
or enter into other arrangements with third parties to provide sales and marketing services for us in place of or to supplement our internal
commercialization infrastructure. We may not be able to secure sales personnel or relationships with third-party sales organizations
that are adequate in number or expertise to successfully market and sell our proprietary formulations, drug products and pharmacy services.
Further, any third-party organizations we may seek to partner with or engage may not be able to provide sales and marketing services
in accordance with our expectations and standards,